Steven James Biography and Net Worth

Director of Allakos

Steven James has over 30 years of biopharmaceutical experience and has been involved in building and leading numerous successful companies and the discovery and development of important approved drug products. Currently, Mr. James is president and Chief Executive Officer and director of Pionyr Immunotherapeutics. Previously, he was president and CEO of Labrys Biologics until it was acquired by Teva Pharmaceuticals. Prior to Labrys, Steve was president and CEO of KAI Pharmaceuticals which was acquired by Amgen. He has held leadership positions at Exelixis, Sunesis Pharmaceuticals, Ionis Pharmaceuticals, and began his career at Eli Lilly. He holds a Masters in Management from the Kellogg School of Northwestern University and an undergraduate degree in neuroscience from Brown University. Steve is currently chairman of Antiva Biosciences and Soteria Therapeutics and a director of Ventus Therapeutics. He was formerly a director of Ocera Inc. (acquired by Mallinkrodt) and Cascadian Therapeutics (acquired by Seattle Genetics).

How do I contact Steven P. James?: The corporate mailing address for Mr. James and other Allakos executives is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. Allakos can also be reached via phone at (650) 597-5002 and via email at ir@allakos.com. Learn More on Steven P. James' contact information.
Has Steven P. James been buying or selling shares of Allakos?: Steven P. James has not been actively trading shares of Allakos during the last quarter. Most recently, Steven P. James sold 4,000 shares of the business's stock in a transaction on Tuesday, September 28th. The shares were sold at an average price of $108.12, for a transaction totalling $432,480.00. Learn More on Steven P. James' trading history.
Who are Allakos' active insiders?: Allakos' insider roster includes Robert Alexander (CEO), Peter Hudson (Major Shareholder), Steven James (Director), Daniel Janney (Director), Robert More (Major Shareholder), Henrik Rassmussen (Insider), and Adam Tomasi (COO). Learn More on Allakos' active insiders.
Are insiders buying or selling shares of Allakos?: During the last twelve months, insiders at the sold shares 1 times. They sold a total of 87,064 shares worth more than $87,934.64. The most recent insider tranaction occured on June, 28th when CFO Harlan Baird Radford sold 87,064 shares worth more than $87,934.64. Insiders at Allakos own 16.1% of the company. Learn More about insider trades at Allakos.
Information on this page was last updated on 6/28/2024.

Steven P. James Insider Trading History at Allakos

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/28/2021	Sell	4,000	$108.12	$432,480.00

Steven P. James Buying and Selling Activity at Allakos

Allakos Company Overview

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Today's Range

Now: $0.23

$0.22

$0.24

50 Day Range

MA: $0.34

$0.23

$1.21

2 Week Range

Now: $0.23

$0.22

$1.56

Volume

734,744 shs

Average Volume

1,003,535 shs

Market Capitalization

$20.76 million

P/E Ratio

N/A

Dividend Yield